Trigg Leslie 4
4 · EXACT SCIENCES CORP · Filed Mar 23, 2026
Research Summary
AI-generated summary of this filing
Exact Sciences (EXAS) Director Trigg Leslie Sells 17,169 Shares in Merger
What Happened
Trigg Leslie, a director of Exact Sciences Corporation (EXAS), recorded two dispositions to the issuer on March 23, 2026: 3,244 shares and 13,925 shares, which were converted into merger consideration in connection with Abbott’s acquisition of Exact Sciences. Under the Merger Agreement each share outstanding (with certain exceptions) was converted into the right to receive $105.00 in cash, so the 17,169 shares equate to roughly $1,802,745 in gross consideration (subject to applicable tax withholding).
Key Details
- Transaction date: March 23, 2026 (Effective Time of the merger).
- Consideration: $105.00 per share under the Merger Agreement (Disposition code D — shares surrendered to the issuer).
- Shares disposed: 3,244 + 13,925 = 17,169 total.
- Approximate gross value: 17,169 × $105 = $1,802,745 (taxes/withholding may reduce net proceeds).
- Shares owned after the transaction: not specified in the filing.
- Footnotes: F1 confirms the Merger with Abbott and the $105 cash consideration; F2 states restricted/vesting shares were deemed fully vested and converted and are subject to withholding.
- Filing timeliness: Reported on the same date (March 23, 2026), so appears timely.
Context
This was not an open-market sale but a cash-out disposition required by the merger—shares were cancelled and converted into the negotiated merger cash consideration. That means the transaction reflects deal mechanics (merger consideration and any tax withholding), not a director-initiated market trade that might signal personal views on the stock.
Insider Transaction Report
- Disposition to Issuer
Common Stock
[F1]2026-03-23−3,244→ 13,925 total - Disposition to Issuer
Common Stock
[F2]2026-03-23−13,925→ 0 total
Footnotes (2)
- [F1]On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the "Issuer"), Abbott Laboratories, an Illinois corporation ("Parent"), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), on the terms and subject to the conditions set forth in the Merger Agreement, each share of the Issuer's common stock, par value $0.01 per share ("Common Stock"), issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive $105.00 in cash, without interest (the "Merger Consideration").
- [F2]At the Effective Time, each share of Common Stock subject to vesting, repurchase or other lapse restriction and that was granted under an Issuer stock plan and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration, less any applicable tax withholding.